VCEL | Vericel Corp |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.09 |
Leverage | 34.05% |
Market Cap | $ 2.8B |
PE | 892.70 |
Dividend Yield | 0.00% |
Profit | $ 3.1m |
Margin | 1.36% |
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.